• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development".

作者信息

Hollis Aidan

机构信息

Department of Economics, University of Calgary and Institute of Health Economics, Calgary, Canada.

出版信息

Pharmacoeconomics. 2005;23(12):1187-92; discussion 1193-202. doi: 10.2165/00019053-200523120-00002.

DOI:10.2165/00019053-200523120-00002
PMID:16336012
Abstract
摘要

相似文献

1
Comment on "The economics of follow-on drug research and development: trends in entry rates and the timing of development".对《后续药物研发的经济学：进入率趋势与研发时机》的评论
Pharmacoeconomics. 2005;23(12):1187-92; discussion 1193-202. doi: 10.2165/00019053-200523120-00002.
2
The economics of follow-on drug research and development: trends in entry rates and the timing of development.仿制药研发的经济学：进入率趋势与研发时机
Pharmacoeconomics. 2004;22(2 Suppl 2):1-14. doi: 10.2165/00019053-200422002-00002.
3
Are the economics of pharmaceutical research and development changing?: productivity, patents and political pressures.制药研发的经济状况正在发生变化吗？：生产率、专利与政治压力。
Pharmacoeconomics. 2004;22(2 Suppl 2):15-24. doi: 10.2165/00019053-200422002-00003.
4
Biotechnology's metamorphosis into a drug discovery industry.
Nat Biotechnol. 1998 May;16 Suppl:22-4. doi: 10.1038/5405.
5
Antibacterial drug discovery: is small pharma the solution?抗菌药物研发：小型制药公司是解决之道吗？
Clin Microbiol Infect. 2004 Nov;10 Suppl 4:32-6. doi: 10.1111/j.1465-0691.2004.1008.x.
6
Drug Discovery Technology and Development 2005 - IBC's Tenth World Congress. Emerging and early stage company showcase pre-conference symposium.药物发现技术与开发2005 - IBC第十届世界大会。新兴及早期阶段公司展示会前研讨会。
IDrugs. 2005 Oct;8(10):796-8.
7
In biomarkers we trust?我们信赖生物标志物？
Nat Biotechnol. 2005 Mar;23(3):297-304. doi: 10.1038/nbt0305-297.
8
Venturing into drug discovery.涉足药物研发。
Nat Biotechnol. 1998 May;16 Suppl:17. doi: 10.1038/5401.
9
Pharmaceutical research: cost savings through innovation.药物研究：通过创新实现成本节约。
AAPPO J. 1993 Oct;3(5):28-36.
10
Deal watch: Trends in platform technology deal-making.交易观察：平台技术交易的趋势
Nat Rev Drug Discov. 2009 Dec;8(12):923. doi: 10.1038/nrd3065.

引用本文的文献

1
Sustainable Financing of Innovative Therapies: A Review of Approaches.创新疗法的可持续融资：方法综述
Pharmacoeconomics. 2016 Oct;34(10):971-80. doi: 10.1007/s40273-016-0416-x.
2
Competitive pricing within pharmaceutical classes: evidence on "follow-on" drugs in Germany 1993-2008.药品类内的竞争定价：德国 1993-2008 年“仿制药”的证据
Eur J Health Econ. 2015 Jan;16(1):73-82. doi: 10.1007/s10198-013-0555-3. Epub 2013 Dec 27.
3
Competitiveness in follow-on drug R&D: a race or imitation?后续药物研发的竞争力：一场竞赛还是模仿？

本文引用的文献

1
Influence of patients' requests for direct-to-consumer advertised antidepressants: a randomized controlled trial.患者对面向消费者宣传的抗抑郁药的需求影响：一项随机对照试验。
JAMA. 2005 Apr 27;293(16):1995-2002. doi: 10.1001/jama.293.16.1995.
2
The economics of follow-on drug research and development: trends in entry rates and the timing of development.仿制药研发的经济学：进入率趋势与研发时机
Pharmacoeconomics. 2004;22(2 Suppl 2):1-14. doi: 10.2165/00019053-200422002-00002.
3
Are novel drugs more risky for patients than less novel drugs?
Nat Rev Drug Discov. 2011 Jan;10(1):23-7. doi: 10.1038/nrd3296. Epub 2010 Dec 10.
新型药物对患者来说是否比非新型药物风险更高？
J Health Econ. 2004 Nov;23(6):1135-58. doi: 10.1016/j.jhealeco.2004.03.007.
4
The Orphan Drug Act: an engine of innovation? At what cost?《孤儿药法案》：创新的引擎？代价几何？
Food Drug Law J. 2000;55(1):125-43.